In a report issued on March 16, Kevin DeGeeter from Oppenheimer reiterated a Buy rating on Humanigen (HGEN – Research Report), with a price target of $16.00. The company's shares closed last Friday at $3.97, close to its 52-week low of $1.67. According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 23.5% and a 38.1% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as BioNano Genomics, Fulgent Genetics, and Exact Sciences. Currently, the analyst consensus on Humanigen is a Strong Buy with an average price target of $21.75, a 491.0% upside from current levels.
https://www.tipranks.com/news/blurbs/oppenheimer-thinks-humanigens-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Humanigen Charts.
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Humanigen Charts.